The battle of the “heartbreak of psoriasis”, my trial is better than yours! BD A new Johnson & Johnson drug trial has put Amgen on the defensive. According to the 903-patient study, J&J's experimental drug ustekinumab (Stelara) proved more effective at treating psoriasis than...
Helpful news for the former employees of Amgen, they get an extension on paying off a 2nd mortgage, but some feel this will help, but still not perhaps save the boat. Pharma layoffs in recent years have primarily been in the area of sales and marketing; however now with mergers, acquisitions...
All over healthcare the big fish, little fish story is either taking place or actions are in the making for offers. There certainly are a number of big Pharma companies with money to foot the bill, that is if the Biotech companies see it fit to consider the options. One problem as indicated in...
Cerner president speaks out about the insurance business, "they need to be redefined". Amgen CEO and President Kevin Sharer called for a better structured FDA . Overall the summary statement says the same thing I have brought up time and time again, who's going to to...
Posted to
The Medical Quack .... by Barbara Duck
on 08-31-2008
Filed under: Medically Related, Insurance, Pharma/FDA News, Other Items of Interest, medicare, health insurance, FDA, Cerner, Amgen, Fixiing Healthcare
Part of the success of Amgen was using a smaller amount of individuals for clinical trials, and looking at results during the trial instead of an overall evaluation process at the conclusion. It also helps keep the cost of the clinical trials down by conducting studies for biomarkers, or signature...